Focus: Locus Biosciences is a public-stage biotechnology company pioneering CRISPR-engineered bacteriophage therapeutics for infectious disease and other indications. The company operates from Morrisville, NC and is positioned at the intersection of synthetic biology and precision medicine.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Locus is a specialized biotech bet for scientists drawn to novel modalities and early-stage risk, but limited hiring and opaque financials make it a high-uncertainty career move.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Locus Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Locus Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight GlobeNewswire
Allies in Innovation: Forging a Transatlantic Biotechnology Partnership to Meet the China Challenge - Center for European Policy Analysis (CEPA)
Allies in Innovation: Forging a Transatlantic Biotechnology Partnership to Meet the China Challenge Center for European Policy Analysis (CEPA)
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli - Pharmaceutical Technology
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli Pharmaceutical Technology
Top Human Microbiome Innovators Transforming Gut Health - SNS Insider
Top Human Microbiome Innovators Transforming Gut Health SNS Insider
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
High-throughput methods leveraging robotics and computer vision for the development of therapeutic phage cocktails.
Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo